Hemostemix Inc. Stock

HEM

CA4236943060

Biotechnology & Medical Research

Market Closed - Toronto S.E. 03:56:07 30/10/2026 HKT			5-day change	1st Jan Change
0.0600 ^CAD	0.00%		+9.09%	-33.33%

10-08	Hemostemix Inc. Receives Full LARTA Approval For Commercial Phase 1 Study Of VesCell And Provides ACP-01 Manufacturing Progress	CI
09-01	Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

News in other languages: Hemostemix Inc.

11/02/25	Hemostemix : Casino auf gold
15/01/25	Hemostemix: Klininsche Studien bescheinigen bahnbrechende Stammzelltherapie
23/04/21	Hemostemix : (German Translation) Hemostemix gibt den Abschluss der Nachbeobachtung von Studienteilnehmern der klinischen Phase-II-Studie bekannt und Uplisting von HMTXF
10/04/21	Hemostemix : (German Translation – April 8, 2021)

More news

Managers and Directors: Hemostemix Inc.

Manager	Title	Age	Since
Thomas Smeenk CEO	Chief Executive Officer	-	10/02/2020
Christina Wu DFI	Director of Finance/CFO	-	05/03/2020
Fraser Henderson CTO	Chief Tech/Sci/R&D Officer	-	14/10/2021

Director	Title	Age	Since
Thomas Smeenk BRD	Director/Board Member	-	26/11/2019
Ronnie Hershmann BRD	Director/Board Member	67	09/02/2020
Loran Swanberg BRD	Director/Board Member	-	08/04/2020

More insiders

Hemostemix Inc. is an autologous stem cell therapy platform company. The Company has developed, patented, and is scaling and selling autologous (patientâ€™s own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01), later neural cell precursors (NCP-01), and cardiomyocyte cell precursors (CCP-01). It holds 91 patents on the derivation of three stem cell lineages from the patientâ€™s blood, including ACP-01, CCP-01 and NCP-01. ACP-01 is a clinically relevant and statistically significant treatment for peripheral arterial disease, chronic limb-threatening ischemia, non-ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. It has completed a Phase II clinical trial for chronic limb-threatening ischemia. It has two wholly owned subsidiaries, Kwalata Trading Limited and PreCerv Inc. PreCerv Inc. holds a global field of use license to ACP-01 & NCP-01 for the treatment of conditions of the central and peripheral nervous system.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
29/10/26	CA$0.0600	0.00%	95,200
28/10/26	CA$0.0600	+9.09%	73,000
27/10/26	CA$0.0550	0.00%	6,300
23/10/26	CA$0.0550	0.00%	28,274
22/10/26	CA$0.0550	-8.33%	2,000

Delayed Quote Toronto S.E.

More quotes

Market Cap	12.69M 9.09M 8.14M 7.49M 6.79M 863M 12.92M 89.32M 35.86M 454M 34.12M 33.4M 1.43B	P/E 2024	-4.36x	P/E 2025	-3.12x
Enterprise Value	15.55M 11.14M 9.98M 9.18M 8.32M 1.06B 15.84M 109M 43.94M 557M 41.82M 40.93M 1.76B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	80.48%	Yield 2024 *	-	Yield 2025	-

Markets		Quality
Toronto S.E.	HEM	Delayed
OTC Markets	HMTXF	Delayed
Deutsche Boerse AG	2VF0	Delayed
Börse Stuttgart	2VF0	Delayed
Tradegate	2VF0	Real-time

10-08	Hemostemix Inc. Receives Full LARTA Approval For Commercial Phase 1 Study Of VesCell And Provides ACP-01 Manufacturing Progress	CI
09-01	Hemostemix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-21	Hemostemix Commercializes Its Vascular Dementia Clinical Trial of Vescell(Tm) Under Larta	CI
07-31	Hemostemix Raises C$322,250 From Second Tranche of Private Placement	MT
07-09	Hemostemix Files Commercialization Application for Treatment of Vascular Dementia, Refractory Angina and Pain	MT
06-26	Hemostemix Raises C$360,000 in the First Tranche of Private Placement of Share Units	MT
06-17	Hemostemix Inc. amended terms of the transaction	CI
05-30	Hemostemix Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-26	Hemostemix Inc. Announces the Appointment of Desire´e Cox to Board of Directors	CI
05-21	Hemostemix Inc. announced that it expects to receive CAD 1 million in funding	CI
05-01	Hemostemix Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
05-01	Hemostemix Inc. Auditor Raises 'Going Concern' Doubt	CI
03-19	Hemostemix Inc. announced that it has received CAD 0.783968 million in funding	CI

10-08	Hemostemix Announces Full LARTA Approval, Manufacturing Progress and Financing Update	NE
09-29	Hemostemix to Attend Centurion One Capital's 4th Annual Bahamas Summit	NE
09-24	Hemostemix Non Brokered Private Placement	NE
08-20	Hemostemix Commercializes Its Vascular Dementia Clinical Trial of VesCell(TM) Under LARTA	NE
08-13	Hemostemix : Dr. Ernst von Schwarz named PI of Hemostemix Longevity Clinical Trial	PU

1 week	0.05	0.06
1 month	0.05	0.08
Current year	0.04	0.11
1 year	0.04	0.11
3 years	0.04	0.42
5 years	0.04	0.42
10 years	0	5

Hemostemix Inc. Stock

Stocks

HEM

CA4236943060

Biotechnology & Medical Research

Valuation: Hemostemix Inc.

Chart: Hemostemix Inc.

Latest news: Hemostemix Inc.

Press Releases: Hemostemix Inc.

News in other languages: Hemostemix Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Hemostemix Inc.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Date	Insider	Type	Main position	Quantity	% Market Cap.
30/7/26	Peter Lacey	Option	Chairman	525,000	0.2654%
22/7/26	Loran Swanberg	Option	Director	385,000	0.1946%
22/7/26	Thomas Smeenk	Option	Founder	1,730,000	0.8746%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
HEMOSTEMIX INC.	0.00%	+9.09%	-36.84%	-29.41%	9.09M
WUXI APPTEC CO., LTD.	-0.62%	-1.87%	+46.31%	+56.99%	63.77B
ARGENX SE	+0.35%	+3.20%	+14.92%	+84.55%	56.37B
LONZA GROUP AG	+0.53%	+1.96%	+15.37%	+106.81%	54.62B
IQVIA HOLDINGS INC.	-2.81%	-4.31%	+23.50%	+50.90%	44.06B
BEONE MEDICINES AG	-0.33%	-1.93%	+20.15%	+98.45%	42.11B
REVOLUTION MEDICINES, INC.	+0.55%	+2.31%	+224.97%	+942.56%	41B
GENMAB A/S	+3.27%	+47.96%	+112.67%	+96.48%	34.92B
CELLTRION, INC.	+1.22%	-1.44%	+14.89%	+47.15%	32.82B
INSMED INCORPORATED	+0.89%	+20.55%	-42.03%	+373.03%	24.7B
Average	+0.31%	+7.69%	+39.39%	+182.75%	39.44B
Weighted average by Cap.	+0.18%	+5.44%	+48.50%	+186.12%

	2024	2025
Net sales	-	-
Net income	-2.62M -1.88M -1.68M -1.54M -1.4M -178M -2.67M -18.42M -7.4M -93.66M -7.04M -6.89M -295M	-4.71M -3.38M -3.03M -2.78M -2.52M -321M -4.8M -33.19M -13.32M -169M -12.68M -12.41M -532M
Net Debt	4.23M 3.03M 2.72M 2.5M 2.26M 288M 4.31M 29.79M 11.96M 151M 11.38M 11.14M 478M	2.86M 2.05M 1.84M 1.69M 1.53M 195M 2.91M 20.14M 8.09M 102M 7.69M 7.53M 323M